Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Dorado

Internal Medicine Westerville, OH Medical Doctor

NPI 1033194949 CMS profile 273908

625 Africa Rd Ste 360, Westerville, OH 43082

Open in the dashboard

General payments

$15,161

970 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Dorado of Westerville, OH is reported in the CMS Open Payments database as having received $15,161 across 970 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,066 105
2024 General $2,118 110
2023 General $2,456 165
2022 General $2,629 184
2021 General $2,091 136
2020 General $1,512 107
2019 General $2,289 163

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Dorado
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to James Dorado were reported at $2,066. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year James Dorado Internal Medicine median Middle half National median
2019 $2,289 $159 $48–$570 $163
2020 $1,512 $119 $33–$402 $114
2021 $2,091 $135 $37–$521 $132
2022 $2,629 $141 $42–$496 $149
2023 $2,456 $149 $45–$519 $160
2024 $2,118 $154 $47–$537 $164
2025 $2,066 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,271 187 payments
  2. Novo Nordisk Inc $1,713 126 payments
  3. AstraZeneca Pharmaceuticals LP $1,430 73 payments
  4. GlaxoSmithKline, LLC. $1,085 84 payments
  5. Lilly USA, LLC $974 61 payments
  6. Janssen Pharmaceuticals, Inc $718 47 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $687 49 payments
  8. Pfizer Inc. $510 30 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $385 19 payments
  10. Amgen Inc. $384 26 payments
  11. Other $5,004 268 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,116 966 payments
  2. Education $46 4 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,329 101 payments
  2. Ozempic $1,040 78 payments
  3. FARXIGA $956 41 payments
  4. RYBELSUS $817 60 payments
  5. TRELEGY ELLIPTA $773 65 payments
  6. QULIPTA $616 54 payments
  7. XARELTO $512 29 payments
  8. JARDIANCE Diabetes $480 37 payments
  9. JARDIANCE Diabetes $417 27 payments
  10. LINZESS $408 23 payments
  11. Other $12,309 756 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 97 drugs

Part D claims

4,166

Median for Internal Medicine: 777

Drug cost

$437,150

Median for Internal Medicine: $73,373

Branded share of claims

24.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 47 $55,740
Jardiance Empagliflozin Brand 50 $55,088
Ozempic Semaglutide Brand 49 $53,230
Trulicity Dulaglutide Brand 37 $52,911
Januvia Sitagliptin Phosphate Brand 42 $50,533
Xarelto Rivaroxaban Brand 23 $32,468
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $22,699
Farxiga Dapagliflozin Propanediol Brand 20 $21,221
Linzess Linaclotide Brand 22 $19,177
Tresiba Flextouch U-200 Insulin Degludec Brand 20 $12,496

The 10 drugs with the highest cost, of 97 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 131 billing codes

Paid by Medicare

$79,023

Of which drugs: $14,132

Medicare patients

155

Average age 73

Services billed

3,207

75 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 48%
Diabetes 35%
Chronic kidney disease 34%
Ischemic heart disease 32%
Depression 28%
Atrial fibrillation 19%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 19 19 $5,513
Vaccine for influenza for injection into muscle 90662 Office 58 60 $4,808
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 23 23 $3,485

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$199 20 —
UBRELVY
$145 — —
XYWAV
$126 — —
QULIPTA
$110 — —
VRAYLAR
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

970 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record